Adirna Therapeutics
Targeting the Dark Genome via Programmable and Scalable Innovation
Adirna Therapeutics
Targeting the Dark Genome via Programmable and Scalable Innovation
About Us
Our Technology Platforms
Our Technology Platforms
Adirna Therapeutics focuses on the untapped potential of the dark genome to revolutionize RNA-based precision medicine. By leveraging AI/ML and big data, Adirna is at the forefront of identifying and validating novel targets within the non-coding regions of the genome, and developing first-in-class or best-in-class therapeutics that address unmet needs.
Our Technology Platforms
Our Technology Platforms
Our Technology Platforms
Adirna Therapeutics has built a comprehensive and proprietary disease-associated non-coding RNA database, and is developing a suite of technology platforms for ncRNA target discovery, ncRNA biomarker discovery, oligonucleotides (such as ASO) and small molecule drug discovery for ncRNA targets, oligonucleotide drug delivery.
Scalable Innovation
Our Technology Platforms
Scalable Innovation
We adopt an open-innovation partnership model that allows us to leverage vast capabilities and highly valuable technologies and assets. We actively seek partnerships to accelerate innovation including, but not limited to, research collaboration, licensing, co-development, acquisition, and joint venture.